Inpharma 1656 - 20 Sep 2008

1

■ Proteon Therapeutics’ development programme gets fast track status. The US FDA has awarded fast track designation to the company’s development programme for PRT 201. This novel recombinant human elastase is being studied for its ability to improve arteriovenous fistula surgery outcomes in patients requiring long-term haemodialysis. Proteon Therapeutics Inc. Proteon Receives FDA Fast Track Designation for First Drug Candidate PRT-201. Media Release : 11 Sep 2008. Available from: 809093000 URL: http://www.proteontherapeutics.com

1173-8324/10/1656-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

Inpharma 20 Sep 2008 No. 1656